UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

	☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

		For the quarterly period ended ~~June~~September 30, 2022

	☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

		For the transition period from ___________ to ___________

Commission File Number: 001-34951

XTANT MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware		20-5313323
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

664 Cruiser Lane Belgrade, Montana		59714
(Address of principal executive offices)		(Zip Code)

(406) 388-0480

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.000001 per share		XTNT		NYSE American LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

	Large accelerated filer ☐		Accelerated filer ☐
	Non-accelerated filer ☒		Smaller reporting company ☒
			Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Number of shares of common stock, $0.000001 par value per share, of registrant outstanding at ~~August 2,~~November 1, 2022: ~~87,313,701~~108,659,388.

XTANT MEDICAL HOLDINGS, INC.

FORM 10-Q

~~June~~September 30, 2022

TABLE OF CONTENTS

		~~Page~~
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS		iiii
PART I.	FINANCIAL INFORMATION	1
ITEM 1.	FINANCIAL STATEMENTS	1
ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	1314
ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	1820
ITEM 4.	CONTROLS AND PROCEDURES	1820
PART II.	OTHER INFORMATION	1920
ITEM 1.	LEGAL PROCEEDINGS	1920
ITEM 1A.	RISK FACTORS	1920
ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	1920
ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	2319
ITEM 4.	MINE SAFETY DISCLOSURES	1923
ITEM 5.	OTHER INFORMATION	1923
ITEM 6.	EXHIBITS	1923

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. For more information, see “Cautionary Statement Regarding Forward-Looking Statements.”

As used in this report, unless the context indicates another meaning, the terms “we,” “us,” “our,” “Xtant,” “Xtant Medical,” and the “Company” mean Xtant Medical Holdings, Inc. and its wholly owned subsidiaries, Xtant Medical, Inc., Bacterin International, Inc., and X-spine Systems, Inc., all of which are consolidated on Xtant’s condensed consolidated financial statements. All intercompany balances and transactions have been eliminated in consolidation.

We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

We include our website address throughout this report for reference only. The information contained on or connected to our website is not incorporated by reference into this report.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements include, but are not limited to, statements regarding our ~~expectations, hopes, beliefs, intentions,~~“expectations,” “hopes,” “beliefs,” “intentions,” or ~~strategies~~“strategies” regarding the future. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” and “would,” as well as similar expressions, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward looking. Forward-looking statements in this Form 10-Q may include, for example, statements about the topics below and are subject to risks and uncertainties including without limitation those described below:

●

the effect of labor and staffing shortages at hospitals and other medical facilities on the number of elective procedures in which our products are used, which have adversely affected and may continue to adversely affect our revenues, as well as global and local labor shortages and loss of personnel, which have adversely affected and may continue to adversely affect our ability to produce product to meet demand;

●

the effect of inflation, increased interest rates and other recessionary indicators and supply chain disruptions, which could result in reduced procedures delayed product launches, lost revenue, higher costs, decreased profit margins, and other adverse effects on our business and operating results;

	●	the effect of the global novel strain of coronavirus (COVID-19) pandemic and current and future variants on our business, operating results and financial condition, including our revenues primarily as a result of the reduction in procedures in which our products are used and the disruption to our customers, distributors, independent sales representatives, contract manufacturers and suppliers, as well as the global economy, supply chain and financial and credit markets;

	●	the effect of labor and staffing shortages at hospitals and other medical facilities on the number of elective procedures in which our products are used, which have adversely affected and may continue to adversely affect our revenues, as well as global and local labor shortages and loss of personnel, which have adversely affected and may continue to adversely affect our ability to produce product to meet demand;

	●	the effect of inflation, other recessionary indicators and supply chain disruptions, which could result in delayed product launches, lost revenue, higher costs, decreased profit margins, and other adverse effects on our business and operating results;

	●	our ability to increase or maintain revenue or return to pre-COVID-19 revenue levels within an acceptable time period or at all and possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory if unsuccessful;

	●	the ability of our sales personnel, including our independent sales agents and distributors, to achieve expected results;

	●	our ability to innovate, develop, introduce and market new products and technologies;

	●	our ability to remain competitive;

	●	our reliance on third party suppliers and manufacturers;

	●	our ability to attract, retain and engage qualified technical, sales and processing personnel and members of our management team, especially in light of a tight labor market and increasing cost of living in and around the Belgrade, Montana area;

	●	our dependence on and ability to retain and recruit independent sales agents and distributors and motivate and incentive them to sell our products, including in particular our dependence on key independent agents for a significant portion of our revenue;

●

our ability to retain and expand our agreements with group purchasing organizations (“GPOs” and independent delivery networks (“IDNs”) and sell products to members of such GPOs and IDNs;

	●	our ability and success in implementing key growth and process improvement initiatives designed to increase our production capacity, revenue and scale and risks associated with such growth and process improvement initiatives;

	●	the effect of our private label and original equipment manufacturer (“OEM”) business on our business and operating results and risks associated therewith, including fluctuations in our operating results and decreased profit margins;

	●	risks associated with and the effect of a shift in procedures using our products from hospitals to ambulatory surgical centers, which would put pressure on the price of our products and margins;

	●	our ability to obtain and maintain government and third-party coverage and reimbursement for our products;

	●	our ability to obtain and maintain regulatory approvals in the United States and abroad and the effect of government regulations and our compliance with government regulations;

	●	our ability to continue to ~~implement a~~realize enhancements related to our new enterprise resource planning (“ERP”) system;

	●	our ability to successfully complete and integrate future business combinations or acquisitions;

	●	the effect of product liability claims and other litigation to which we may be subjected and product recalls and defects;

	●	our ability to remain accredited with the American Association of Tissue Banks and continue to obtain a sufficient number of donor cadavers for our products;

	●	our ability to obtain and protect our intellectual property and proprietary rights and operate without infringing the intellectual property rights of others;

	●	the availability of our credit facilities;

	●	~~our ability to service our debt and comply with the covenants in our credit agreements;~~

	●	our ability to maintain sufficient liquidity to fund our operations and obtain financing on reasonable terms when needed; ~~and~~

●

our anticipated use of net proceeds from our recent private placement and the possible effect of future resales of shares sold in the private placement on the trading price of our common stock;

●

our ability to service our debt and comply with the covenants in our credit agreements;

●

our expectations regarding higher product costs continuing to adversely affect our gross profit as a percentage of revenue in future periods; and

●

our ability to maintain our stock listing on the NYSE American Exchange.

The forward-looking statements contained in this Form 10-Q are based on our current expectations and beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties, or assumptions, many of which are beyond our control, which may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2021 and this Form 10-Q.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.

iii

PART I.

FINANCIAL INFORMATION

~~PART I. FINANCIAL INFORMATION~~

~~ITEM 1. FINANCIAL STATEMENTS~~

ITEM 1.

FINANCIAL STATEMENTS

XTANT MEDICAL HOLDINGS, INC.

Condensed Consolidated Balance Sheets

(In thousands, except number of shares and par value)


	As of June 30, 2022			As of December 31, 2021			As of September 30, 2022			As of December 31, 2021
	(Unaudited)						(Unaudited)
ASSETS
Current Assets:
Cash and cash equivalents	$	16,495		$	18,243		$	17,363		$	18,243
Restricted cash		352			144			240			144
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $510 and $552, respectively		8,600			7,154
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $549 and $552, respectively								9,839			7,154
Inventories		16,461			17,945			16,993			17,945
Prepaid and other current assets		424			844			673			844
Total current assets		42,332			44,330			45,108			44,330
Property and equipment, net		5,529			5,212			5,669			5,212
Right-of-use asset, net		1,033			1,258			1,490			1,258
Goodwill		3,205			3,205			3,205			3,205
Intangible assets, net		372			400			358			400
Other assets		242			287			219			287
Total Assets	$	52,713		$	54,692		$	56,049		$	54,692

LIABILITIES & STOCKHOLDERS’ EQUITY
Current Liabilities:
Accounts payable	$	3,043		$	2,615		$	3,779		$	2,615
Accrued liabilities		4,538			4,349			5,021			4,349
Current portion of lease liability		479			462			443			462
Current portion of finance lease obligations		60			31			61			31
Line of credit		3,736			3,620			720			3,620
Current portion of long-term debt								1,335			—
Total current liabilities		11,856			11,077			11,359			11,077
Long-term Liabilities:
Lease liability, less current portion		598			842			1,094			842
Finance lease obligation, less current portion		213			103			197			103
Long-term debt, plus premium and less issuance costs		11,902			11,787			10,626			11,787
Total Liabilities		24,569			23,809			23,276			23,809
Commitments and Contingencies (note 11)		—			—
Commitments and Contingencies (Note 11)								-
Stockholders’ Equity:
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding		—			—
Common stock, $0.000001 par value; 300,000,000 shares authorized; 87,313,701 shares issued and outstanding as of June 30, 2022 and 87,068,980 shares issued and outstanding as of December 31, 2021		—			—
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding								—			—
Common stock, $0.000001 par value; 300,000,000 shares authorized; 101,981,250 shares issued and outstanding as of September 30, 2022 and 87,068,980 shares issued and outstanding as of December 31, 2021								—			—
Additional paid-in capital		267,252			266,068			274,234			266,068
Accumulated deficit		(239,108	)		(235,185	)		(241,461	)		(235,185	)
Total Stockholders’ Equity		28,144			30,883			32,773			30,883
Total Liabilities & Stockholders’ Equity	$	52,713		$	54,692		$	56,049		$	54,692

See notes to unaudited condensed consolidated financial statements.

XTANT MEDICAL HOLDINGS, INC.

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except number of shares and per share amounts)

	2022			2021				2022			2021			2022			2021			2022			2021
	Three Months Ended June 30,							Six Months Ended June 30,						Three Months Ended September 30,						Nine Months Ended September 30,
	2022			2021				2022			2021			2022			2021			2022			2021
Revenue
Orthopedic product sales	$	15,277		$	14,942			$	28,227		$	27,451		$	14,462		$	13,743		$	42,689		$	41,193
Other revenue		—			33				9			66			—			34			10			100
Total Revenue		15,277			14,975				28,236			27,517			14,462			13,777			42,699			41,293
							��
Cost of sales		6,903			5,460				12,302			9,911			6,566			6,586			18,868			16,498
Gross Profit		8,374			9,515				15,934			17,606			7,896			7,191			23,831			24,795

Operating Expenses
General and administrative		3,797			4,173				7,766			7,200			3,729			3,107			11,496			10,307
Sales and marketing		5,636			5,590				10,845			10,445			5,838			5,267			16,683			15,712
Research and development		241			243				454			458			229			262			683			719
Total Operating Expenses		9,674			10,006				19,065			18,103			9,796			8,636			28,862			26,738

Loss from Operations		(1,300	)		(491	)			(3,131	)		(497	)		(1,900	)		(1,445	)		(5,031	)		(1,943	)

Other Expense
Interest expense		(397	)		(199	)			(757	)		(201	)		(440	)		(329	)		(1,197	)		(529	)
Total Other Expense		(397	)		(199	)			(757	)		(201	)		(440	)		(329	)		(1,197	)		(529	)

Net Loss Before Provision for Income Taxes		(1,697	)		(690	)			(3,888	)		(698	)		(2,340	)		(1,774	)		(6,228	)		(2,472	)

Provision for Income Taxes Current and Deferred		(13	)		(43	)			(35	)		(64	)		(13	)		(30	)		(48	)		(94	)
Net Loss	$	(1,710	)	$	(733	)		$	(3,923	)	$	(762	)	$	(2,353	)	$	(1,804	)	$	(6,276	)	$	(2,566	)

Net Loss Per Share:
Net loss per share:
Basic	$	(0.02	)	$	(0.01	)		$	(0.04	)	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.07	)	$	(0.03	)
Dilutive	$	(0.02	)	$	(0.01	)		$	(0.04	)	$	(0.01	)	$	(0.03	)	$	(0.02	)	$	(0.07	)	$	(0.03	)

Shares used in the computation:
Basic		87,313,701			86,707,286				87,252,521			83,993,159			93,278,610			86,763,210			89,236,832			84,926,656
Dilutive		87,313,701			86,707,286				87,252,521			83,993,159			93,278,610			86,763,210			89,236,832			84,926,656

See notes to unaudited condensed consolidated financial statements.

XTANT MEDICAL HOLDINGS, INC.

Condensed Consolidated Statements of Equity

(Unaudited, in thousands, except number of shares)

	Shares		Amount		Capital		Deficit			Equity			Shares		Amount		Capital		Deficit			Equity
	Common Stock				Additional Paid-In-		Accumulated			Total Stockholders’			Common Stock				Additional Paid-In-		Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Equity			Shares		Amount		Capital		Deficit			Equity
Balance at December 31, 2021		87,068,980	$	—	$	266,068	$	(235,185	)	$	30,883			87,068,980	$	—	$	266,068	$	(235,185	)	$	30,883

Common stock issued on vesting of restricted stock units		244,721		—		—		—			—
Private placement of common stock, net of issuance costs of $1,926
Private placement of common stock, net of issuance costs of $1,926, shares
Warrants issued in connection with the private placement
Warrants issued in connection with the private placement to placement agents
Gain on debt extinguishment
Common stock issued on vesting of restricted stock units														244,721		—		—		—			—
Withholding of common stock upon vesting of restricted stock units
Withholding of common stock upon vesting of restricted stock units, shares
Stock-based compensation		—		—		613		—			613			—		—		613		—			613
Net loss		—		—		—		(2,213	)		(2,213	)		—		—		—		(2,213	)		(2,213	)
Balance at March 31, 2022		87,313,701		—		266,681		(237,398	)		29,283			87,313,701		—		266,681		(237,398	)		29,283

Stock-based compensation		—		—		571		—			571			—		—		571		—			571
Net loss		—		—		—		(1,710	)		(1,710	)		—		—		—		(1,710	)		(1,710	)
Balance at June 30, 2022		87,313,701	$	—	$	267,252	$	(239,108	)	$	28,144			87,313,701				267,252		(239,108	)		28,144

Private placement of common stock, net of issuance costs of $409														14,060,315		—		5,225		—			5,225
Warrants issued in connection with the private placement														—		—		1,116		—			1,116
Common stock issued on vesting of restricted stock units														607,234		—		—		—			—
Stock-based compensation														—		—		641		—			641
Net loss														—		—		—		(2,353	)		(2,353	)
Balance at September 30, 2022														101,981,250	$	—	$	274,234	$	(241,461	)	$	32,773

	Common Stock				Additional Paid-In-		Accumulated			Total Stockholders’			Common Stock					Additional Paid-In-			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Equity			Shares			Amount		Capital			Deficit			Equity
Balance at December 31, 2020		77,573,680	$	—	$	244,850	$	(230,336	)	$	14,514			77,573,680		$	—	$	244,850		$	(230,336	)	$	14,514

Private placement of common stock, net of issuance costs of $1,926		8,888,890		—		12,831		—			12,831			8,888,890			—		12,831			—			12,831
Warrants issued in connection with the private placement		—		—		5,243		—			5,243			—			—		5,243			—			5,243
Warrants issued in connection with the private placement to placement agents		—		—		351		—			351			—			—		351			—			351
Common stock issued on vesting of restricted stock units		244,716		—		—		—			—			244,716			—		—			—			—
Stock-based compensation		—		—		456		—			456			—			—		456			—			456
Net loss		—		—		—		(29	)		(29	)		—			—		—			(29	)		(29	)
Balance at March 31, 2021		86,707,286		—		263,731		(230,365	)		33,366			86,707,286			—		263,731			(230,365	)		33,366
Beginning balance, value		86,707,286		—		263,731		(230,365	)		33,366

Stock-based compensation		—		—		465		—			465			—			—		465			—			465
Gain on debt extinguishment		—		—		786		—			786			—			—		786			—			786
Net loss		—		—		—		(733	)		(733	)		—			—		—			(733	)		(733	)
Balance at June 30, 2021		86,707,286	$	—	$	264,982	$	(231,098	)	$	33,884			86,707,286			—		264,982			(231,098	)		33,884
Ending balance, value		86,707,286	$	—	$	264,982	$	(231,098	)	$	33,884
Beginning balance														86,707,286			—		264,982		$	(231,098	)		33,884
Common stock issued on vesting of restricted stock units														104,856			—		—			—			—
Withholding of common stock upon vesting of restricted stock units														(15,967	)		—		(23	)		—			(23	)
Stock-based compensation														—			—		580			—			580
Net loss														—			—		—			(1,804	)		(1,804	)
Balance at September 30, 2021														86,796,175		$	—	$	265,539		$	(232,902	)	$	32,637
Ending balance														86,796,175		$	—	$	265,539		$	(232,902	)	$	32,637

See notes to unaudited condensed consolidated financial statements.

XTANT MEDICAL HOLDINGS, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited, in thousands)

	2022			2021			2022			2021
	Six Months Ended June 30,						Nine Months Ended September 30,
	2022			2021			2022			2021
Operating activities:
Net loss	$	(3,923	)	$	(762	)	$	(6,276	)	$	(2,566	)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:
Depreciation and amortization		599			731			971			1,041
Gain on disposal of fixed assets		(84	)		(108	)		(91	)		(164	)
Non-cash interest		116			16			175			38
Non-cash rent		(1	)		5			2			8
Stock-based compensation		1,184			921			1,825			1,501
Provision for reserve on accounts receivable		143			(143	)
Provision for reserve (recovery) on accounts receivable								277			(25	)
Provision for excess and obsolete inventory		825			211			1,568			572

Changes in operating assets and liabilities:
Accounts receivable		(1,589	)		38			(2,962	)		584
Inventories		659			104			(616	)		1,128
Prepaid and other assets		465			(29	)		239			(126	)
Accounts payable		428			(308	)		1,164			(592	)
Accrued liabilities		189			266			671			(1,383	)
Net cash (used in) provided by operating activities		(989	)		942			(3,053	)		16

Investing activities:
Purchases of property and equipment and intangible assets		(810	)		(1,079	)		(1,321	)		(1,489	)
Proceeds from sale of fixed assets		165			125			184			194
Net cash used in investing activities		(645	)		(954	)		(1,137	)		(1,295	)

Financing activities:
Payment of taxes from withholding of common stock on vesting of restricted stock units								—			(23	)
Payments on financing leases		(22	)		(34	)		(35	)		(42	)
Costs associated with refinancing		—			(32	)		—			(136	)
Payments on long-term debt		—			(484	)		—			(411	)
Borrowings on line of credit		26,567			9,331			36,680			22,767
Repayments of line of credit		(26,451	)		(9,009	)		(39,580	)		(23,029	)
Proceeds from private placement, net of cash issuance costs		—			18,426			6,341			18,426
Net cash provided by financing activities		94			18,198			3,406			17,552

Net change in cash and cash equivalents and restricted cash		(1,540	)		18,186			(784	)		16,273
Cash and cash equivalents and restricted cash at beginning of period		18,387			2,341			18,387			2,341
Cash and cash equivalents and restricted cash at end of period	$	16,847		$	20,527		$	17,603		$	18,614

Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets
Cash and cash equivalents	$	16,495		$	20,312		$	17,363		$	18,175
Restricted cash		352			215			240			439
Total cash and restricted cash reported in the condensed consolidated balance sheets	$	16,847		$	20,527		$	17,603		$	18,614

See notes to unaudited condensed consolidated financial statements.

Notes to Unaudited Condensed Consolidated Financial Statements

(1) Business Description, Basis of Presentation and Summary of Significant Accounting Policies

Business Description and Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Xtant Medical Holdings, Inc. (“Xtant”), a Delaware corporation, and its wholly owned subsidiaries, Xtant Medical, Inc. (“Xtant Medical”), a Delaware corporation, Bacterin International, Inc. (“Bacterin”), a Nevada corporation, and X-spine Systems, Inc. (“X-spine”), an Ohio corporation (Xtant, Xtant Medical, Bacterin, and X-spine are jointly referred to herein as the “Company” or sometimes “we,” “our,” or “us”). All intercompany balances and transactions have been eliminated in consolidation.

Xtant is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures.

At the onset of, and at various times during, the COVID-19 pandemic, hospitals and other medical facilities cancelled or deferred elective procedures, diverted resources to patients suffering from infections and limited access for non-patients, including our direct and indirect sales representatives. Especially during waves of increased cases and hospitalizations, surgeons and their patients have been required or chosen to defer procedures in which our products otherwise would be used, and many facilities that specialize in the procedures in which our products otherwise would be used have experienced temporary closures or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and may continue to have a material adverse effect on our revenues.

The accompanying condensed consolidated balance sheet as of December 31, 2021, which has been derived from audited financial statements, and the unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. They do not include all disclosures required by generally accepted accounting principles for annual consolidated financial statements, but in the opinion of management include all adjustments, consisting only of normal recurring items, necessary for a fair presentation.

Interim results are not necessarily indicative of results that may be achieved in the future for the full year ending December 31, 2022.

These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto, which are included in Xtant’s Annual Report on Form 10-K for the year ended December 31, 2021. The accounting policies set forth in those annual consolidated financial statements are the same as the accounting policies utilized in the preparation of these condensed consolidated financial statements, except as modified for appropriate interim consolidated financial statement presentation.

Private Placement

On August 25, 2022, the Company closed the first tranche of a private placement (the “First Closing”) with several accredited investors (the “Private Placement”). At the First Closing, the Company sold approximately 14.1 million shares of common stock of the Company (collectively, the “Shares”) and warrants to purchase approximately 3.5 million shares of common stock (collectively, the “Warrants”) for an aggregate purchase price of approximately $6.75 million. We received net cash proceeds of approximately $6.3 million, after deducting fees and other estimated offering expenses, from the First Closing.

The closing of the second tranche of the Private Placement (the “Second Closing”) occurred on October 7, 2022. At the Second Closing, the Company sold an additional approximately 6.2 million shares of common stock of the Company and warrants to purchase approximately 1.6 million shares of common stock for an aggregate purchase price of approximately $3.0 million.

The Warrants, described in more detail in Note 10, “Warrants”, have an exercise price of $0.48 per share, are subject to customary anti-dilution, but not price protection, adjustments, are immediately exercisable and expire on the five-year anniversary of the First Closing.

Use of Estimates

The preparation of the condensed consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the period. Significant estimates include the carrying amount of property and equipment, goodwill and intangible assets and liabilities, valuation allowances for trade receivables, inventory and deferred income tax assets and liabilities, current and long-term lease obligations and corresponding right-of-use asset and estimates for the fair value of long-term debt, stock options and other equity awards upon which the Company determines stock-based compensation expense. Actual results could differ from those estimates.

Restricted Cash

Cash and cash equivalents classified as restricted cash on our condensed consolidated balance sheets are restricted as to withdrawal or use under the terms of certain ~~contractual~~credit agreements. The ~~June~~September 30, 2022 balance included lockbox deposits that are temporarily restricted due to timing at the period end. The lockbox deposits are applied against our line of credit the next business day.

Long-Lived Assets

The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recovered. No impairments of long-lived assets were recorded for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.

Goodwill

Goodwill represents the excess of costs over fair value of assets of businesses acquired. Goodwill and intangible assets acquired in a purchase business combination and determined to have indefinite useful lives are not amortized. Instead, they are tested for impairment at least annually, and whenever events or circumstances indicate, the carrying amount of the asset may not be recoverable. No impairments of goodwill were recorded for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding. Shares issued during the period and shares reacquired during the period are weighted for the portion of the period that they were outstanding. Diluted net loss per share is computed in a manner consistent with that of basic earnings per share while giving effect to all potentially dilutive shares of common stock outstanding during the period, which include the assumed exercise of stock options and warrants using the treasury stock method. Diluted net loss per share was the same as basic net loss per share for the three and six months ended June 30, 2022 and 2021, as shares issuable upon the exercise of stock options and warrants were anti-dilutive as a result of the net losses incurred for those periods. Our diluted earnings per share is the same as basic earnings per share, as the effects of including ~~12,474,376~~17,192,048 and ~~11,982,139~~14,138,224 outstanding stock options, restricted stock units and warrants for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021, respectively, are anti-dilutive.

Fair Value of Financial Instruments

The carrying values of financial instruments, including trade accounts receivable, accounts payable, accrued liabilities, and long-term debt, approximate their fair values based on terms and related interest rates as of ~~June~~September 30, 2022 and December 31, 2021.

(2) Revenue

In the United States, we generate most of our revenue from independent commissioned sales agents. We consign our orthobiologics products to hospitals and consign or loan our spinal implant sets to the independent sales agents. The spinal implant sets typically contain the instruments, disposables, and spinal implants required to complete a surgery. Consigned sets are managed by the sales agent to service hospitals that are high volume users for multiple procedures.

We ship replacement inventory to independent sales agents to replace the consigned inventory used in surgeries. Loaned sets are returned to the Company’s distribution center, replenished, and made available to sales agents for the next surgical procedure.

For each surgical procedure, the sales agent reports use of the product by the hospital and, as soon as practicable thereafter, ensures that the hospital provides a purchase order to the Company. Upon receipt of the hospital purchase order, the Company invoices the hospital, and revenue is recognized in the proper period. Additionally, the Company sells product directly to domestic and international stocking resellers and private label resellers. Upon receipt and acceptance of a purchase order from a stocking reseller, the Company ships product and invoices the reseller. The Company recognizes revenue when control of the promised goods is transferred to the customer, in an amount that reflects the consideration the Company expects to collect in exchange for those goods or services. There is generally no customer acceptance or other condition that prevents the Company from recognizing revenue in accordance with the delivery terms for these sales transactions.

The Company operates in one reportable segment with ~~our~~its net revenue derived primarily from the sale of ~~orthobiologics~~orthopaedic medical products and ~~spinal implant products~~devices across North America, Europe, Asia Pacific, and Latin America. Sales are reported net of returns. The following table presents revenues from these product lines for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 (in thousands):

Summary of Revenues from Product Lines

	Three Months Ended		Percentage of			Three Months Ended		Percentage of
	June 30, 2022		Total Revenue			June 30, 2021		Total Revenue			Three Months Ended September 30, 2022		Percentage of Total Revenue			Three Months Ended September 30, 2021		Percentage of Total Revenue
Orthobiologics	$	12,402		81	%	$	11,460		77	%	$	12,046		83	%	$	10,795		78	%
Spinal implant		2,875		19	%		3,482		23	%		2,416		17	%		2,948		22	%
Other revenue		—		0	%		33		0	%		—		0	%		34		0	%
Total revenue	$	15,277		100	%	$	14,975		100	%	$	14,462		100	%	$	13,777		100	%

	Nine Months Ended September 30, 2022		Percentage of Total Revenue			Nine Months Ended September 30, 2021		Percentage of Total Revenue
Orthobiologics	$	34,614		81	%	$	31,264		76	%
Spinal implant		8,075		19	%		9,929		24	%
Other revenue		10		0	%		100		0	%
Total revenue	$	42,699		100	%	$	41,293		100	%

Six Months
Ended

Percentage of

Six Months
Ended

Percentage of

June 30, 2022 Total Revenue June 30, 2021 Total Revenue
Orthobiologics $ 22,568 80 % $ 20,471 75 %
Spinal implant 5,659 20 % 6,980 25 %
Other revenue 9 0 % 66 0 %
Total revenue $ 28,236 100 % $ 27,517 100 %

(3) Receivables

The Company’s provision for current expected credit loss is determined based on historical collection experience adjusted for current economic conditions affecting collectability. Actual customer collections could differ from estimates. Account balances are charged to the allowance after all means of collection have been exhausted and the potential for recovery is considered remote. Provisions to the allowance for credit losses are charged to expense. Activity within the allowance for credit losses was as follows for the three ~~months~~ and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021 (in thousands):

Schedule of Allowance for Credit Losses

June 30, 2022 June 30, 2021
Balance at January 1 $ 552 $ 653
Provision for expected credit losses 191 (63 )
Write-offs charged against allowance (173 ) (36 )
Balance at March 31 570 554
Provision for expected credit losses (49 ) (81 )
Write-offs charged against allowance (11 ) (3 )
Balance at June 30 $ 510 $ 470

	September 30, 2022			September 30, 2021
Balance at January 1	$	552		$	653
Provision for current expected credit losses		191			(63	)
Write-offs charged against allowance		(173	)		(36	)
Balance at March 31		570			554
Provision for current expected credit losses		(49	)		(81	)
Write-offs charged against allowance		(11	)		(3	)
Balance at June 30		510			470
Provision for current expected credit losses		54			118
Write-offs charged against allowance		(15	)		(12	)
Balance at September 30	$	549		$	576

(4) Inventories

Inventories consist of the following (in thousands):

Schedule of Inventories

	June 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
Raw materials	$	5,034	$	5,613	$	5,121	$	5,613
Work in process		856		571		957		571
Finished goods		10,571		11,761		10,915		11,761
Total	$	16,461	$	17,945	$	16,993	$	17,945

(5) Property and Equipment, Net

Property and equipment, net are as follows (in thousands):

Schedule of Property and Equipment, Net

	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
Equipment	$	5,854		$	5,541		$	6,302		$	5,541
Computer equipment		1,090			828			1,090			828
Computer software		490			490			490			490
Furniture and fixtures		94			94			104			94
Leasehold improvements		4,327			3,994			4,333			3,994
Other		10			10			10			10
Surgical instruments		11,319			11,424			11,307			11,424
Total cost		23,184			22,381			23,636			22,381
Less: accumulated depreciation		(17,655	)		(17,169	)		(17,967	)		(17,169	)
Property and equipment, net	$	5,529		$	5,212		$	5,669		$	5,212

Depreciation expense related to property and equipment, including property under finance leases, for the three months ended ~~June~~September 30, 2022 and 2021 was $~~0.3~~0.4 million and $0.3 million, respectively, and $~~0.6~~1 ~~million and $0.7~~ million for both the ~~six~~nine months ended ~~June~~September 30, 2022 and ~~2021, respectively.~~2021.

(6) Intangible Assets

The following table sets forth information regarding intangible assets (in thousands):

Schedule of Intangible Assets

	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
Patents	$	847		$	847		$	807		$	847
Accumulated amortization		(475	)		(447	)		(449	)		(447	)
Intangible assets, net	$	372		$	400		$	358		$	400

(7) Accrued Liabilities

Accrued liabilities consist of the following (in thousands):

Schedule of Accrued Liabilities

June 30, 2022 December 31, 2021
Cash compensation/commissions payable $ 3,556 $ 3,184
Other accrued liabilities 982 1,165
Accrued liabilities $ 4,538 $ 4,349

	September 30, 2022		December 31, 2021
Cash compensation/commissions payable	$	3,844	$	3,184
Other accrued liabilities		1,177		1,165
Accrued liabilities	$	5,021	$	4,349

(8) Debt

Long-term debt consists of the following (in thousands):

Schedule of Long-term Debt

	June 30, 2022			December 31, 2021			September 30, 2022			December 31, 2021
Amounts due under the Term Facility	$	12,000		$	12,000		$	12,000		$	12,000
Accrued end-of-term payments		149			83			182			83
Less: unamortized debt issuance costs		(247	)		(296	)		(221	)		(296	)
Less: current maturities		—			—			(1,335	)		—
Long-term debt	$	11,902		$	11,787		$	10,626		$	11,787

On March 7, 2022, the Company’s term loan agreement and revolving credit agreement were amended to, among other things, (i) provide for a waiver of compliance with respect to the Company’s minimum adjusted EBITDA requirement if and so long as the Company’s liquidity (as specifically defined in the term loan agreement and revolving credit agreement) is in excess of $14 million and there is not otherwise an event of default under the term loan agreement and revolving credit agreement, commencing March 31, 2022, and (ii) re-set the date certain fees payable in connection with optional prepayments are determined to the date the amendment was executed and consequently extend such fees’ original expiration. In addition, the final payment fees associated with the term loan were increased by 25 basis points.

The effective rate of the term loan, inclusive of amortization of debt issuance costs and accretion of the final payment, was ~~10.03~~11.53% as of ~~June~~September 30, 2022. The effective rate of the revolving credit agreement was ~~5.57~~7.07% as of ~~June~~September 30, 2022. As of ~~June~~September 30, 2022, the Company had $~~4.1~~7.3 million available under the revolving credit agreement.

On October 27, 2022, the Company’s term loan and revolving credit agreements were amended to transition the reference rate from LIBOR to term SOFR. The term SOFR reference rate will apply to amounts outstanding and draws that place on or after November 1, 2022.

(9) Stock-Based Compensation

Stock option activity, including options granted under the Xtant Medical Holdings, Inc. 2018 Equity Incentive Plan, as amended (the “2018 Plan”), and the Amended and Restated Xtant Medical Equity Incentive Plan and options granted to new hires to purchase shares of our common stock outside of any stockholder-approved plan, was as follows for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Schedule of Share-based Compensation, Stock Options, Activity

2022 2021
Shares
Weighted
Average
Exercise Price Per Share

Weighted
Average Remaining Contractual Term (years)
Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Term (years)
Outstanding at January 1 3,201,666 $ 1.80 2,190,892 $ 2.25
Granted 109,164 0.65 — —
Cancelled or expired (443,125 ) $ 2.39 (125 ) $ 372.00
Outstanding at June 30 2,867,705 $ 1.66 8.4 2,190,767 $ 2.23 9.1
Exercisable at June 30 599,063 $ 2.71 7.8 122,614 $ 14.38 7.4

~~As of June 30, 2022, there was approximately $2.0~~ ~~million of total unrecognized compensation expense related to unvested stock options. These costs are expected to be recognized over a weighted-average period of~~ ~~2.6~~ ~~years. The weighted average grant date fair value of options granted during the six months ended June 30, 2022 was $0.55~~.

	2022							2021
	Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contract Term (years)		Shares			Weighted Average Exercise Price Per Share		Weighted Average Remaining Contract Term (years)
Outstanding at January 1		3,201,666		$	1.80				2,190,892		$	2.25
Granted		109,164		$	0.65				1,012,083		$	1.27
Cancelled or expired		(443,125	)	$	2.39				(269	)	$	314.19
Outstanding at September 30		2,867,705		$	1.66		8.1		3,202,706		$	1.92		9.1
Exercisable at September 30		828,978		$	2.37		7.8		210,028		$	9.02		7.4

Restricted stock unit activity for awards granted under the 2018 Plan was as follows for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021:

Schedule of Restricted Stock Activity

	2022					2021					2022					2021
	Shares			Weighted Average Fair Value at Grant Date Per Share		Shares			Weighted Average Fair Value at Grant Date Per Share		Shares			Weighted Average Fair Value at Grant Date Per Share		Shares			Weighted Average Fair Value at Grant Date Per Share
Outstanding at January 1		2,970,104		$	1.39		2,503,698		$	1.54		2,970,104		$	1.39		2,503,698		$	1.54
Granted		88,983		$	0.65		-		$	-		1,898,808		$	0.53		1,249,002		$	1.27
Vested		(244,721	)	$	1.45		(244,716	)	$	1.45		(851,955	)	$	1.33		(349,572	)	$	1.92
Cancelled		(318,807	)	$	1.32		-		$	-		(318,805	)	$	1.38		—		$	—
Outstanding at June 30		2,495,559		$	1.36		2,258,982		$	1.54
Outstanding at September 30												3,698,152		$	0.96		3,403,128		$	1.40

At the 2022 annual meeting of stockholders held on October 26, 2022, our shareholders approved an amendment to the 2018 Plan to increase the number of shares of common stock available thereunder by 8,500,000 shares.

(10) Warrants

As noted in Note 1, “Business Description, Basis of ~~June 30,~~Presentation and Summary of Significant Accounting Policies,” on August 25, 2022, ~~and December 31, 2021, there were warrants~~the Company issued the Warrants. The Warrants meet all the requirements to ~~purchase~~ ~~7,111,112~~be classified as equity awards in accordance with Accounting Standards Codification (“ASC”) No. 815-40. The number of shares of ~~our~~Company common stock ~~outstanding at~~issuable upon exercise of the Warrants is subject to standard and customary anti-dilution provisions for stock splits, stock dividends, or similar transactions. In addition, the Warrants include a ~~weighted average exercise price~~buy-out right whereby the holders of $~~2.29~~ ~~per share.~~such warrants may put the warrants back to the Company or its successor in the event of a purchase, tender or exchange offer accepted by 50% or more of the Company’s holders of common stock and not approved by the Company’s board of directors. The buy-out amount is equal to the Black-Scholes value of the warrants on the date the triggering transaction is consummated based on certain inputs as defined in the Warrant agreement. The consideration to be paid if the buy-out provision is triggered shall be in the same type or form of consideration that is being offered and paid to the holders of Company common stock in connection with the triggering transaction.

While the Warrants are classified as a component of equity, we were required to allocate the proceeds of the Private Placement between the shares of common stock and the Warrants issued based on their relative fair values. The fair value of the Warrants, $0.40 per warrant, issued in connection with the Private Placement was determined using a Black Scholes model. Significant assumptions in the model included contractual term (5 years) and the estimated volatility factor of the Company’s stock (107%).

Our warrant activity during the nine months ended September 30, 2022 was as follows:

Schedule of Warrant Activity

	Common Stock Warrants		Weighted Average Exercise Price
Outstanding at January 1, 2022		7,111,112	$	2.29
Issued		3,515,079		0.48
Outstanding at September 30, 2022		10,626,191	$	1.69

(11) Commitments and Contingencies

Operating Leases

We lease three office facilities as of ~~June~~September 30, 2022 in Belgrade, Montana under non-cancelable operating lease ~~agreements with expiration dates between 2023 and 2025. We have the option to extend certain leases by five or ten-year term(s), and we have the right of first refusal on any sale. As of June 30, 2022, the weighted-average remaining lease term was~~agreements. ~~2.6~~ ~~years.~~ On July 14, 2022, the Company’s lease agreement for facilities at 600 Cruiser Lane in Belgrade, Montana was amended to, among other things, extend the lease term through October ~~2025.~~2025 to align the lease term with the Company’s lease agreement for facilities at 664 Cruisier Lane in Belgrade, Montana. In addition,~~Othe~~ the Company’s lease agreement for facilities at 732 Cruiser Lane in Belgrade, Montana was amended on July 29, 2022 to extend the lease term through October 2025. We have the option to extend certain leases to five or ten-year term(s), and we have the right of first refusal on any sale. As of September 30, 2022, the weighted-average remaining lease term was 3.1 years.

Present Value of Long-term Leases

Schedule of Lease Liability

(in thousands):	June 30, 2022		September 30, 2022
Right-of-use assets, net	$	1,033	$	1,490

Current portion of lease liability		479	$	443
Lease liability, less current portion		598		1,094
Total lease liability	$	1,077	$	1,537

Future minimum payments for the next five years and thereafter as of ~~June~~September 30, 2022 under these long-term operating leases are as follows (in thousands):

Schedule of Future Minimum Rental Payments for Operating Leases


Remainder of 2022	$	262			131
2023		489			534
2024		224			559
2025		179			470
Total future minimum lease payments		1,154			1,694
Less amount representing interest		(77	)		(157	)
Present value of obligations under operating leases		1,077			1,537
Less current portion		(479	)		(443	)
Long-term operating lease obligations	$	598		$	1,094

Rent expense was $0.1 million for both the three months ended ~~June~~September 30, 2022 and 2021 and $~~0.3~~0.4 million for both the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021. We have no contingent rent agreements.

1011

Litigation

We are subject to potential liabilities under government regulations and various claims and legal actions that are pending or may be asserted from time to time. These matters arise in the ordinary course and conduct of our business and may include, for example, commercial, product liability, intellectual property, and employment matters. When we believe that a loss is probable and reasonably estimable, we record a charge on our condensed consolidated statements of operations for our estimated loss. We do not believe that the ultimate resolution of any such potential liabilities, claims or legal actions will have a material adverse effect upon our consolidated financial position, results of operations, or cash flows.

~~Indemnification Arrangements~~Indemnifications

Our indemnification arrangements generally include limited warranties and certain provisions for indemnifying customers against liabilities if our products or services infringe a third-party’s intellectual property rights. To date, we have not incurred any material costs as a result of such warranties or indemnification provisions and have not accrued any liabilities related to such obligations in the accompanying condensed consolidated financial statements.

We have also agreed to indemnify our directors and executive officers for costs associated with any fees, expenses, judgments, fines, and settlement amounts incurred by any of these persons in any action or proceeding to which any of those persons is, or is threatened to be, made a party by reason of the person’s service as a director or officer, including any action by us, arising out of that person’s services as our director or officer or that person’s services provided to any other company or enterprise at our request.

(12) Income Taxes

In evaluating the realizability of the net deferred tax assets, we take into account a number of factors, primarily relating to the ability to generate taxable income. Where it is determined that it is likely that we will be unable to realize deferred tax assets, a valuation allowance is established against the applicable portion of the deferred tax asset. Because it cannot be accurately determined when or if we will become profitable, a valuation allowance was provided against the entire deferred income tax asset balance.

The Company did not recognize any interest or penalties related to income taxes for the three and ~~six~~nine months ended ~~June~~September 30, 2022 and 2021.

(13) Supplemental Disclosure of Cash Flow Information

Supplemental cash flow information is as follows (in thousands):

Schedule of Supplemental Cash Flow Information

	2022		2021		2022		2021
	Six Months Ended				Nine Months Ended
	June,				September 30,
	2022		2021		2022		2021
Supplemental disclosure of cash flow information
Cash paid during the period for:
Interest	$	667	$	185	$	1,022	$	485
Non-cash activities:
Fixed assets acquired under finance lease	$	159	$	163	$	159	$	163
Revaluation of lease liability and right of use asset					$	234	$	—
Gain on extinguishment of Second A&R Credit Agreement	$	—	$	786	$	—	$	786
Extinguishment of Second A&R Credit Agreement financed by line of credit	$	—	$	3,755	$	—	$	3,755
Prepaid debt issuance costs					$	—	$	75
Warrants issued in connection with the Private Placement to placement agents	$	—	$	351	$	—	$	351

(14) Related Party Transactions

As described in more detail under Note 1, “Business Description and Summary of Significant Accounting Policies” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, we are party to an Investor Rights Agreement, Registration Rights Agreements and certain other agreements with OrbiMed Royalty Opportunities II, LP (“Royalty Opportunities”) and ROS Acquisition Offshore LP (“ROS”), which are funds affiliated with OrbiMed Advisors LLC (“OrbiMed”). OrbiMed beneficially owns 8472%% of the Company’s common stock.

All related party transactions are reviewed and approved by the Audit Committee or the disinterested members of the full Board of Directors.

(15) Segment and Geographic Information

The Company’s management reviews financial results and manages the business on an aggregate basis. Therefore, financial results are reported in a single operating segment: the development, manufacture, and marketing of orthopedic medical products and devices.

The Company attributes revenues to geographic areas based on the location of the customer. Approximately 9999%% of sales were in the United States for the three months ended ~~June~~September 30, 2022 and 2021, and 9999%% for the ~~six~~nine months ended ~~June~~September 30, 2022 and 2021. Total revenue by major geographic area is as follows (in thousands):

Schedule of Revenues by Geographic Region

	Three Months Ended June 30,				Three Months Ended September 30,
	2022		2021		2022		2021
United States	$	15,025	$	14,891	$	14,370	$	13,629
Rest of world		252		84		92		148
Total revenue	$	15,277	$	14,975	$	14,462	$	13,777

	Six Months Ended June 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
United States	$	27,719	$	27,184	$	42,089	$	40,813
Rest of world		517		333		610		480
Total revenue	$	28,236	$	27,517	$	42,699	$	41,293

1213

~~ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS~~

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. The following discussion should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and accompanying notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties, and assumptions. Some of the numbers included herein have been rounded for the convenience of presentation. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed above in “Cautionary Statement Regarding Forward-Looking Statements” and elsewhere in this Form 10-Q.

Business Overview

We develop, manufacture and market regenerative medicine products and medical devices for domestic and international markets. Our products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease. We promote our products in the United States through independent distributors and stocking agents, supported by direct employees.

We have an extensive sales channel of independent commissioned agents and stocking distributors in the United States representing some or all of our products. We also maintain a national accounts program to enable our agents to gain access to integrated delivery network hospitals (“IDNs”) and through group purchasing organizations (“GPOs”). We have biologics contracts with major GPOs, as well as extensive access to IDNs across the United States for both biologics and spine hardware systems. While our focus is the United States market, we promote and sell our products internationally through stocking distribution partners in Canada, Mexico, South America, Australia, and certain Pacific region countries.

We have focused and intend to continue to focus primarily on four key growth initiatives: (1) introduce new products; (2) expand our distribution network; (3) penetrate adjacent markets; and (4) leverage our growth platform with technology and strategic acquisitions. Xtant has continued to experience growth from the two new products introduced in 2021, and we will continue to focus on growing those lines. Concurrently, our penetration into certain adjacent markets has slowed due to recently limited availability of production labor in our local area. Initiatives are underway to improve our recruitment, training capabilities and production levels in order to better penetrate new market opportunities. While the intent of these four key growth initiatives is to increase our future revenues, no assurance can be provided that we will be successful in implementing these growth initiatives or increasing our future revenues.

Recent Private Placement

On August 25, 2022, we issued in the first tranche of a private placement with several accredited investors approximately 14.1 million shares of our common stock at a purchase price of $0.48 per share and warrants to purchase approximately 3.5 million shares of our common stock. The warrants have an exercise price of $0.48 per share, are subject to customary anti-dilution, but not price protection, adjustments, are immediately exercisable and expire on the five-year anniversary of the date of issuance. We received net cash proceeds of approximately $6.3 million, after deducting fees and other estimated offering expenses, from the private placement. The closing of the second tranche of the private placement occurred on October 7, 2022, at which we sold an additional approximately 6.2 million shares of our common stock and warrants to purchase approximately 1.6 million shares of common stock for an aggregate purchase price of approximately $3.0 million. The warrants issued at the second closing are identical to the warrants issued at the first closing and also expire on the five-year anniversary of the first closing. We expect to use these net proceeds for working capital and other general corporate purposes.

Impact of the COVID-19 Pandemic

~~Since March 2020, the COVID-19 pandemic has caused business closures, severe travel restrictions and implementation of social distancing measures.~~ At the onset of, and at various times during, the COVID-19 pandemic, hospitals and other medical facilities have cancelled or deferred elective procedures, diverted resources to patients suffering from infections, and limited access for non-patients, including our direct and indirect sales representatives. Because of these circumstances, surgeons and their patients have deferred, and may continue to defer, procedures in which our products otherwise would be used. In addition, many facilities that specialize in procedures in which our products are used have experienced, and may continue to experience, staffing shortages, temporary closures, and/or reduced operating hours. These circumstances have negatively impacted, and may continue to negatively impact, the number of elective procedures being conducted and the ability of our employees, independent sales representatives and distributors to effectively market and sell our products, which has had and may continue to have a material adverse effect on our revenues.

During the first quarter of 2022, spine and other surgery procedure volumes were negatively impacted in many of our key markets, due to cancellations and/or postponements of procedures as a result of hospitalizations of COVID-19 patients, restrictions on elective procedures and staffing shortages in our key markets, which negatively impacted our first quarter 2022 revenues. This reduction in elective procedures and staffing shortages subsided during the second quarter of 2022, but could reoccur if there is another wave or sustained resurgence of COVID-19 cases and hospitalizations.

The COVID-19 pandemic also has caused and may continue to cause adverse effects on general commercial activity and the global economy and supply chain, disrupting our ability to obtain raw materials, components and products. The pandemic has also adversely affected, and may continue to adversely affect, our distributors, independent sales representatives, customers, contract manufacturers and suppliers and their respective businesses, which in turn, have adversely affected, and may continue to adversely affect, our business and operations.

Although we continue to monitor the impact of the COVID-19 pandemic on our business, operations and financial results, the full extent to which the COVID-19 pandemic will continue to impact our business during the remainder of 2022 will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 variants, actions taken to contain or treat the impact of COVID-19, the availability, acceptance and effectiveness of vaccines, future resurgences of the virus and its variants, the level of any government restrictions, patient capacity at hospitals and healthcare systems, and the willingness and ability of patients to seek care and treatment due to safety concerns or financial hardship. If our revenues continue to decline and do not recover to pre-COVID-19 pandemic levels, we may be required to incur impairment charges to our long-lived assets and goodwill and write-off excess inventory, which would likely adversely affect our future operating results.

Results of Operations

Comparison of Three and ~~Six~~Nine Months Ended ~~June~~September 30, 2022 and ~~June~~September 30, 2021

Revenue

Total revenue for the three and ~~six~~nine months ended ~~June~~September 30, ~~2021~~2022 was ~~$15.3~~$14.5 million and ~~$28.2~~$42.7 million, respectively, which represents ~~an increase~~increases of 2%5% and 3%, respectively, compared to ~~$15.0~~$13.8 million and ~~$27.5~~$41.3 million for the three and ~~six~~nine months ended ~~June~~September 30, 2021, respectively. These revenue increases are attributed primarily to introductions of new products, specifically OsteoVive® Plus and ~~increased private label and original equipment manufacturer sales.~~OsteoFactor™.

Cost of Sales and Gross Profit

Cost of sales consists primarily of manufacturing and product purchase costs as well as depreciation of surgical trays. Cost of sales also includes reserves for estimated excess inventory, inventory on consignment that may be missing and not returned, and reserves for estimated missing and damaged consigned surgical instruments. Cost of sales ~~increased by 26%, or $1.4 million, to $6.9~~of $6.6 million for the three months ended ~~June~~September 30, 2022 ~~from $5.5 million for~~was comparable to the ~~three months ended June 30, 2021.~~same prior year period. Cost of sales increased by ~~24%~~14%, or $2.4 million, to ~~$12.3~~$18.9 million for the ~~six~~nine months ended ~~June~~September 30, 2022 from ~~$9.9~~$16.5 million for the ~~six~~nine months ended ~~June~~September 30, 2021. ~~These increases~~The increase in cost of sales ~~are~~for the nine month comparison is primarily due to ~~higher production costs and~~ additional expense of $1.0 million related to increased reserve expense for ~~the write-down of~~ excess and obsolete ~~inventory.~~inventory and additional salaries and wages expense of $0.6 million with the remaining increase relating primarily to higher sales levels.

Gross profit as a percentage of revenue ~~decreased~~increased to ~~54.8%~~54.6% for the three months ended ~~June~~September 30, 2022 compared to ~~63.5%~~52.2% for the same period in 2021 and decreased to ~~56.4%~~55.8% for the ~~six~~nine months ended ~~June~~September 30, 2022 compared to ~~64.0%~~60.0% for the same period in 2021. Of the ~~decrease~~increase for the ~~three month~~three-month comparison, ~~360 basis points were due to higher product costs, 300~~200 basis points resulted from ~~increased charges~~sales mix including greater higher margin independent agent sales and 400 basis points resulted from additional absorption of labor and overhead, partially offset by 280 basis points resulting from additional reserve expense for excess and obsolete ~~inventory and~~ ~~220~~ ~~basis points~~ ~~were due to sales mix including greater sales of lower margin private label and original equipment manufacturer products and lower sales of higher margin spinal implants.~~inventory. Of the decrease for the ~~six month~~nine-month comparison, ~~390 basis points were due to higher product costs,~~ 220 basis points resulted from ~~increased charges~~higher product costs and 240 basis points results from additional reserve expense for excess and obsolete ~~inventory and~~inventory. ~~200~~ ~~basis points~~ ~~were due to sales mix including greater sales of lower margin private label and original equipment manufacturer products and lower sales of higher margin spinal implants.~~ We expect higher product costs to continue to adversely affect our gross profit as a percentage of revenue in future periods.

General and Administrative

General and administrative expenses consist principally of personnel costs for corporate employees, cash-based and stock-based compensation related costs, legal, accounting and professional fees, and occupancy costs. General and administrative expenses ~~decreased 9%~~increased 20%, or ~~$0.4~~$0.6 million, to ~~$3.8~~$3.7 million for the three months ended ~~June~~September 30, 2022, compared to ~~$4.2~~$3.1 million for the same period in 2021. General and administrative expenses ~~increased 8%, or $0.6 million, to $7.8~~were $11.5 million for the ~~six~~nine months ended ~~June~~September 30, 2022, an increase of 12%, or $1.2 million, compared to ~~$7.2 million for~~ the same period in 2021. The ~~decrease~~increase for the three-month comparison is primarily attributable to ~~legal settlement expenses~~additional expense of ~~$0.6~~$0.3 million ~~incurred during the prior year period.~~related to product registrations and additional expense of $0.3 million related to various employee compensation plans. The increase for the ~~six-month~~nine-month comparison ~~is primarily attributable to~~includes additional bad debt expense of $0.3 million, ~~increased~~additional expense of $0.3 million related to ~~licenses and fees,~~product registrations, additional ~~stock based~~stock-based compensation of $0.3 million and costs related to ERP system upgrades of ~~$0.2~~$0.5 million, ~~incurred~~ ~~during the six months ended June 30, 2022,~~ partially offset by legal settlement expenses of $0.6 million during the prior year ~~period.~~period.

Sales and Marketing

Sales and marketing expenses consist primarily of sales commissions, personnel costs for sales and marketing employees, costs for trade shows, sales conventions and meetings, travel expenses, advertising, and other sales and marketing related costs. Sales and marketing expenses ~~were $5.6~~increased 11%, or $0.6 million, to $5.9 million for ~~both~~ the three months ended ~~June~~September 30, 2022, ~~and~~compared to $5.3 million for the ~~prior year period.~~same period of 2021. Sales and marketing expenses increased 4%6%, or ~~$0.4~~$1.0 million, to ~~$10.8~~$16.7 million for the ~~six~~nine months ended ~~June~~September 30, 2022, compared to ~~$10.4~~$15.7 million for the ~~prior year period.~~same period of 2021. The increase for the ~~six-month~~three-month comparison is primarily due to ~~increased~~additional independent agent sales commissions and incentives of $0.6 million due to higher revenues versus the comparable period in 2021. The increase for the nine-month comparison is primarily due to additional salaries and wages related to higher headcount and additional independent agent sales commissions and incentives of ~~$0.2~~$0.6 million due to ~~additional headcount~~higher revenues versus the comparable period in 2021.

Research and Development

Research and development expenses consist primarily of internal costs for the development of new technologies and processes. Research and development expenses ~~were~~decreased 13% or $0.1 million, to $0.2 million for ~~both~~ the three months ended ~~June~~September 30, 2022, ~~and 2021 and $0.5~~compared to $0.3 million for ~~both~~ the ~~six~~three months ended ~~June~~September 30, 2021. Research and development expenses of $0.7 million for the nine months ended September 30, 2022 ~~and~~was comparable to the prior year period. The decrease for the three-month comparison is primarily due to reduced equipment purchases versus the comparable period in 2021.

Interest Expense

Interest expense consists of interest incurred from our debt instruments. Interest expense was $0.4 million ~~and $0.8~~for the three months ended September 30, 2022 compared to $0.3 million for the three ~~and six~~ months ended ~~June~~September 30, ~~2022, respectively, compared to $0.2 million and $0.2~~2021. Interest expense was $1.2 million for the ~~three and six~~nine months ended ~~June~~September 30, 2022 and $0.5 million for the nine months ended September 30, 2021. ~~These~~The increase in interest expense during the three months ended September 30, 2022 compared to the comparable period in the prior year resulted primarily from increases to the base interest rate applied to our debt instruments. The increase in interest expense during the nine months ended September 30, 2022 compared to the comparable period in the prior year resulted from our debt refinancing in May 2021, prior to which no interest expense related to our debt instruments was incurred during 2021. We expect interest expense to increase in future periods compared to the comparable prior year periods in light of current rising interest rates. We expect that our annualized interest expense will increase approximately $0.1 million for every 75 basis points of increase to the reference rate associated with our credit agreements.

Liquidity and Capital Resources

Working Capital

Since our inception, we have financed our operations through primarily operating cash flows, private placements of equity securities and convertible debt, debt facilities, common stock rights offerings, and other debt transactions. The following table summarizes our working capital as of ~~June~~September 30, 2022 and December 31, 2021 (in thousands):

	June 30, 2022		December 31, 2021		September 30, 2022		December 31, 2021
Cash and cash equivalents	$	16,847	$	18,387	$	17,603	$	18,387
Accounts receivable, net		8,600		7,154		9,839		7,154
Inventories		16,461		17,945		16,993		17,945
Total current assets		42,332		44,330		45,108		44,330
Accounts payable		3,043		2,615		3,779		2,615
Accrued liabilities		4,538		4,349		5,021		4,349
Line of credit		3,736		3,620		720		3,620
Current portion of long-term debt						1,335		—
Total current liabilities		11,856		11,077		11,359		11,077
Net working capital		30,476		33,253		33,749		33,253

Our decrease in cash and cash equivalents was due primarily to ~~the~~net cash used byin operations and reduced borrowing on our ~~net loss~~revolving line of ~~$3.9 million,~~credit, partially offset by ~~stock-based compensation~~the net proceeds from the closing of ~~$1.2~~the first tranche of our August 2022 private placement of common stock and warrants. On August 25, 2022, we issued in the first tranche of a private placement with several accredited investors approximately 14.1 million ~~provision~~shares of our common stock at a purchase price of $0.48 per share and warrants to purchase approximately 3.5 million shares of our common stock. The warrants have an exercise price of $0.48 per share, subject to customary anti-dilution, but not price protection, adjustments, are immediately exercisable and expire on the five-year anniversary of the date of issuance. We received net cash proceeds of approximately $6.3 million, after deducting fees and other estimated offering expenses, from the first tranche of this private placement. The closing of the second tranche of the private placement occurred on October 7, 2022, at which we sold an additional approximately 6.2 million shares of our common stock and warrants to purchase approximately 1.6 million shares of common stock for ~~excess~~an aggregate purchase price of $3.0. The warrants issued at the second closing are identical to the warrants issued at the first closing and ~~obsolete inventory~~also expire on the five-year anniversary of ~~$0.8 million,~~the first closing. We expect to use the net proceeds from this private placement for working capital and ~~depreciation and amortization of $0.6 million.~~other general corporate purposes.

Cash Flows

Net cash used in operating activities for the first ~~six~~nine months of 2022 was ~~$1.0~~$3.1 million. For the comparable period of 2021, net cash provided by operating activities was ~~$0.9 million.~~ $16 thousand. This ~~decrease~~increase in net cash used in operating activities relates primarily to the increase in net loss, partially offset by the effects of changes in operating assets and liabilities.

Net cash used in investing activities for the first ~~six~~nine months of 2022 and 2021 was ~~$0.6~~$1.1 million and ~~$1.0~~$1.3 million, respectively, primarily representing purchases of property and equipment.

Net cash provided by financing activities was $3.4 million for the first ~~six~~nine months of 2022, which was ~~$0.1~~primarily attributable to $6.3 million ~~consisting primarily~~ of ~~borrowings and~~proceeds from the first tranche of our August 2022 private placement, net of issuance costs, partially offset by net repayments on our line ~~credit, and~~of credit. Net cash provided financing activities was ~~$18.2~~$17.6 million for the ~~first six months~~comparable period of 2021, ~~consisting~~which was primarily attributable to $18.4 million of ~~net~~ proceeds from our February 2021 private ~~placement.~~placement, net of issuance costs.

Current and Prior Credit Facilities

On May 6, 2021, the Company, as guarantor, and our subsidiaries, as borrowers (collectively, the “Borrowers”), entered into a Credit, Security and Guaranty Agreement (Term Loan) (the “Term Credit Agreement”) and Credit, Security and Guaranty Agreement (Revolving Loan) (the “Revolving Credit Agreement” and, together with the Term Credit Agreement, the “Credit Agreements”) with MidCap Financial Trust, in its capacity as agent (“MidCap”).

The Term Credit Agreement provides for a secured term loan facility (the “Term Facility”) in an aggregate principal amount of $12.0 million (the “Term Loan Commitment”), which was funded to the Borrowers immediately, and an additional $5.0 million tranche available solely at the discretion of MidCap and the lenders, for the purposes agreed to between the Company, the Borrowers and the lenders in advance of the making of loans under such additional tranche. The Revolving Credit Agreement provides for a secured revolving credit facility (the “Revolving Facility,” and, together with the Term Facility, the “Facilities”) under which the Borrowers may borrow up to $8.0 million (such amount, the “Revolving Loan Commitment”) at any one time, the availability of which is determined based on a borrowing base equal to percentages of certain accounts receivable and inventory of the Borrowers in accordance with a formula set forth in the Revolving Credit Agreement. All borrowings under the Revolving Facility are subject to the satisfaction of customary conditions, including the absence of default, the accuracy of representations and warranties in all material respects and the delivery of an updated borrowing base certificate.

The Facilities have a maturity date of May 1, ~~2026.~~2026 (the “Maturity Date). Beginning in June 2023, the Company is required to make monthly principal payments of approximately $0.3 million on the Term Facility through the Maturity Date. Each of the Borrowers, and the Company, as guarantor, are jointly and severally liable for all of the obligations under the Facilities on the terms set forth in the Credit Agreements. The Borrowers’ obligations, and the Company’s obligations as a guarantor, under the Credit Agreements are secured by first-priority liens on substantially all of their assets, including, without limitation, all inventory, equipment, accounts, intellectual property and other assets of the Company and the Borrowers.

The proceeds of the Term Facility and Revolving Facility were used to pay transaction fees in connection with the Facilities and to pay in full all outstanding indebtedness and accrued interest under the Company’s prior credit facility, which is described below. As of ~~June~~September 30, 2022, the Company had ~~$3.7~~$0.7 million outstanding and ~~$4.1~~$7.3 million of availability under the Revolving Facility. On October 27, 2022, the Credit Agreements were amended to transition the reference rate from LIBOR to term SOFR. The term SOFR reference rate will apply to amounts outstanding and draws that take place on or after the November 1, 2022.

The loans and other obligations pursuant to the Credit Agreements bear interest at a per annum rate equal to the sum of the LIBOR rate, as such term is defined in the Credit Agreements, plus the applicable margin of 7.00% in the case of the Term Credit Agreement, and 4.50% in the case of the Revolving Credit Agreement, subject in each case to a LIBOR floor of 1.00%. As of ~~June~~September 30, 2022, the effective rate of the Term Facility, inclusive of amortization of debt issuance costs and accretion of the final payment, was ~~10.03%~~11.53%, and the effective rate of the Revolving Facility was ~~5.57%~~7.07%.

The Credit Agreements contain affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants that, among other things, limit or restrict the ability of the Borrowers, subject to negotiated exceptions, to incur additional indebtedness and additional liens on their assets, engage in mergers or acquisitions or dispose of assets, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the Credit Agreements require the Borrowers and the Company to maintain net product revenue at or above minimum levels and to maintain a minimum adjusted EBITDA and a minimum liquidity, in each case at levels specified in the Credit Agreements. On March 7, 2022, the Credit Agreements were amended to, among other things, (i) provide for a waiver of compliance with respect to the Company’s minimum adjusted EBITDA requirement if and so long as the Company’s liquidity (as specifically defined in the Credit Agreements) is in excess of $14 million and there is not otherwise an event of default under the Credit Agreements, commencing with the next delivery of the compliance certificate required under the Credit Agreements, and (ii) re-set the date certain fees payable in connection with optional prepayments are determined to the date the amendment was executed and consequently extend such fees’ original expiration. In addition, the exit fees were increased by 25 basis points. As of ~~June~~September 30, 2022, we were in compliance with all covenants under the Credit Agreements.

On May 6, 2021, contemporaneously with the execution and delivery of the Credit Agreements, that certain Second Amended and Restated Credit Agreement, dated March 29, 2019, among the Company, the Borrowers, Royalty Opportunities and ROS, as subsequently amended, which was scheduled to mature on December 31, 2021, was terminated in accordance with the terms thereof and all outstanding amounts were repaid by the Borrowers to OrbiMed Royalty Opportunities II, LP in its role as sole lender thereunder.

Cash Requirements

We believe that our ~~$16.5~~$17.4 million of cash and cash equivalents as of ~~June~~September 30, 2022, together with the net proceeds from the closing of the second tranche of our private placement on October 7, 2022 and amounts available under the Facilities and cash provided by operating activities, will be sufficient to meet our anticipated cash requirements through at least ~~August~~November 2023. However, we may require or seek additional capital to fund our future operations and business strategy prior to ~~August~~November 2023. Accordingly, there is no assurance that we will not need or seek additional financing prior to such time.

We may elect to raise additional financing even before we need it if market conditions for raising additional capital are favorable. We may seek to raise additional financing through various sources, such as equity and debt financings, additional debt restructurings or refinancings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if economic and market conditions deteriorate.

To the extent that we raise additional capital through the sale of equity or convertible debt securities or the restructuring or refinancing of our debt, the interests of our current stockholders may be diluted, and the terms may include discounted equity purchase prices, warrant coverage, ~~and~~ liquidation or other preferences or rights that would adversely affect the rights of our current stockholders. If we issue common stock, we may do so at purchase prices that represent a discount to our ~~then current~~ trading ~~prices~~price and/or we may issue warrants to the purchasers, which could further dilute our current stockholders. If we issue preferred stock, it could adversely affect the rights of our stockholders or reduce the value of our common stock. In particular, specific rights or preferences granted to future holders of preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Additional debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Prior to raising additional equity or debt financing, we may be required to obtain the consent of the Agent under our Credit Agreements and/or ROS and Royalty Opportunities ~~and ROS~~ under our Investor Rights Agreement with them, and no assurance can be provided that they would provide such consent, which could limit our ability to raise additional financing and the terms thereof. In addition, the investors in our recent private placement have certain participation rights with respect to certain future equity offerings for capital raising purposes.

1719

Critical Accounting Estimates

Management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions, and any such differences may be material.

There have been no changes in our critical accounting estimates for the three and ~~six~~nine months ended ~~June~~September 30, 2022 as compared to the critical accounting estimates described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021.

~~ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK~~

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide the information required by this Item.

~~item 4. controls and procedures~~

ITEM 4.

CONTROLS AND PROCEDURES

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as ~~amended (the “Exchange Act”))~~amended) as of ~~June~~September 30, 2022. Based upon that evaluation, our principal executive officer and principal financial officer concluded that as of ~~June~~September 30, 2022, our disclosure controls and procedures were effective.

Changes in Internal Control over Financial Reporting

During the three months ended September 30, 2022, the Company implemented a new enterprise resource planning system. There were no other changes in ~~our~~the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange ~~Act)~~Act of 1934, as amended) during the three months ended ~~June~~September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

18PART II.

OTHER INFORMATION

~~PART II. OTHER INFORMATION~~

ITEM 1.

LEGAL PROCEEDINGS

~~item 1. legal proceedings~~Not applicable.

~~Our legal proceedings are discussed in Note 11 – Commitments and Contingencies in the notes to our condensed consolidated financial statements in this Form 10-Q.~~

~~item 1a. risk factors~~

ITEM 1A.

RISK FACTORS

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

~~item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS~~ We did not sell any unregistered equity securities of our Company during the quarter ended September 30, 2022, other than the issuance of shares of our common stock and warrants in connection with our private placement, as reported in a Current Report on Form 8-K as filed with the SEC on August 24, 2022.

~~Not applicable.~~

~~item 3. DEFAULTS UPON SENIOR SECURITIES~~

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

Not applicable.

~~item 4. MINE SAFETY DISCLOSURES~~

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

~~item 5. OTHER INFORMATION~~On October 27, 2022, the Company’s term loan and revolving credit agreements with MidCap Financial Trust, as agent, were amended to transition the reference rate from LIBOR to term SOFR. The term SOFR reference rate will apply to amounts outstanding and draws that place on or after November 1, 2022.

~~Not applicable.~~The foregoing description of the amendments to the Company’s term loan and revolving credit agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the amendments, which are filed as Exhibits 10.4 and 10.5, respectively, to this Quarterly Report on Form 10-Q and incorporated herein by reference.

~~item 6. EXHIBITS~~

ITEM 6.

EXHIBITS

The following exhibits are being filed or furnished with this Quarterly Report on Form 10-Q:

Exhibit No.		Description
3.1		Amended and Restated Certificate of Incorporation of Xtant Medical Holdings, Inc. (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 13, 2018 (SEC File No. 001-34951) and incorporated by reference herein).

3.2		Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Xtant Medical Holdings, Inc. (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 31, 2019 (SEC File No. 001-34951) and incorporated by reference herein).

3.3		Certificate of Amendment of the Amended and Restated Certificate of Incorporation of Xtant Medical Holdings, Inc., as amended (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on October 1, 2020 (SEC File No. 001-34951) and incorporated by reference herein).

3.4		Second Amended and Restated Bylaws of Xtant Medical Holdings, Inc. (filed as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 16, 2018 (SEC File No. 001-34951) and incorporated by reference herein).

4.1		Form of Warrant Issued to Investors in August 2022 Private Placement (filed as Exhibit 4.1 to the Registrant’s Current Report on Form 8-K as filed with the SEC on August 24, 2022 (SEC File No. 0001-34951) and incorporated by reference herein).

10.1		~~Employment~~Securities Purchase Agreement, ~~effective~~dated as of ~~June 1,~~August 23, 2022, ~~between~~by and among Xtant Medical Holdings, Inc. and ~~Scott Neils~~the investors party thereto (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K as filed with the SEC on ~~May 2,~~August 24, 2022 (SEC File No. ~~001-34951)~~0001-34951) and incorporated by reference herein).

10.2

Registration Rights Agreement by and among Xtant Medical Holdings, Inc. and the investors party thereto (filed as Exhibit 10.2 to the Company’s Current Report on Form 8-K as filed with the SEC on August 31, 2022 (SEC File No. 0001-34951) and incorporated by reference herein).


10.3		Letter Agreement by and between Xtant Medical Holdings, Inc. and Stavros Vizirgianakis (filed as Exhibit 10.3 to the Registrant’s Current Report on Form 8-K as filed with the SEC on August 31, 2022 (SEC File No. 0001-34951) and incorporated by reference herein).

10.4		Amendment No. 2 to Credit, Security and Guaranty Agreement (Term Loan), dated as of October 27, 2022, by and among Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc., and any additional borrower that hereafter becomes party thereto, Xtant Medical Holdings, Inc., and any additional guarantor that hereafter becomes party thereto, and MidCap Financial Trust, as agent, and the lenders from time to time party thereto (filed herewith).

10.5		Amendment No. 2 to Credit, Security and Guaranty Agreement (Revolving Loan), dated as of October 27, 2022, by and among Xtant Medical, Inc., Bacterin International, Inc., X-spine Systems, Inc., and any additional borrower that hereafter becomes party thereto, Xtant Medical Holdings, Inc., and any additional guarantor that hereafter becomes party thereto, and MidCap Financial Trust, as agent, and the lenders from time to time party thereto (filed herewith).

31.1		Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

31.2		Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).

32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith).

101		The following materials from Xtant’s Quarterly Report on Form 10-Q for the fiscal quarter ended ~~June~~September 30, 2022, formatted in Inline XBRL (Extensible Business Reporting Language): (i) the unaudited Condensed Consolidated Balance Sheets, (ii) the unaudited Condensed Consolidated Statements of Operations, (iii) the unaudited Condensed Consolidated Statements of Equity, ~~(Deficit),~~ (iv) the unaudited Condensed Consolidated Statements of Cash Flows, and (v) Notes to Condensed Consolidated Financial Statements (filed herewith).

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2021

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	XTANT MEDICAL HOLDINGS, INC.

Date: ~~August 4,~~November 3, 2022	By:	/s/ Sean E. Browne
	Name:	Sean E. Browne
	Title:	President and Chief Executive Officer
		(Principal Executive Officer)


Date: ~~August 4,~~November 3, 2022	By:	/s/ Scott Neils
	Name:	Scott Neils
	Title:	Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

2122

	Six Months Ended		Percentage of			Six Months Ended		Percentage of
	June 30, 2022		Total Revenue			June 30, 2021		Total Revenue
Orthobiologics	$	22,568		80	%	$	20,471		75	%
Spinal implant		5,659		20	%		6,980		25	%
Other revenue		9		0	%		66		0	%
Total revenue	$	28,236		100	%	$	27,517		100	%

	June 30, 2022			June 30, 2021
Balance at January 1	$	552		$	653
Provision for expected credit losses		191			(63	)
Write-offs charged against allowance		(173	)		(36	)
Balance at March 31		570			554
Provision for expected credit losses		(49	)		(81	)
Write-offs charged against allowance		(11	)		(3	)
Balance at June 30	$	510		$	470